Compare Revvity Inc (RVTY) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Global X SuperDividend ETF — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while Global X SuperDividend ETF trades at $23.96 (market cap $1.17B). The key difference: Revvity Inc is far larger — about 14.5× Global X SuperDividend ETF's market cap, and Revvity Inc pays a 0.18% dividend while Global X SuperDividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Global X SuperDividend ETF for 47 Days on average.
| RVTY | SDIV | |
|---|---|---|
Market Cap | $16.98B | $1.17B |
Volume | 1,456,900 | 387,692 |
Sector | Health | Broad Market / Factor |
52-Week High | $157.36 | $26.34 |
52-Week Low | $82.26 | $22.90 |
Typical Hold Time | 12 Days | 47 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
SDIV trades at $23.96, up 1.61% with a bearish technical outlook from moving averages. The ETF maintains an 8%+ dividend yield but faces significant price erosion, having lost 66% since inception according to Seeking Alpha (2026-09-11). Recent institutional buying includes Ameritas Advisory Services increasing its position by 92.6% in Q2 2026. Technical indicators show mixed signals with neutral oscillators but bearish moving averages and ADX readings.
SDIV offers high income potential but carries substantial principal risk. The fund's deep value approach lacks quality screening, leading to persistent underperformance versus global benchmarks. While monthly dividends attract income seekers, the erosion of capital requires careful risk assessment for long-term investors considering this high-yield strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
